This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Background: We have previously reported the role of anti-angiogenic factors in inducing the transition from compensatory
cardiac hypertrophy to heart failure and the significance of MMP-9 and TIMP-3 in promoting this process during pressure
overload hemodynamic stress. Several studies reported the evidence of cardiac autophagy, involving removal of cellular
organelles like mitochondria (mitophagy), peroxisomes etc., in the pathogenesis of heart failure. However, little is known
regarding the therapeutic role of mitochondrial division inhibitor (Mdivi) in the pressure overload induced heart failure. We
hypothesize that treatment with mitochondrial division inhibitor (Mdivi) inhibits abnormal mitophagy in a pressure overload
heart and thus ameliorates heart failure condition.
Materials and Methods: To verify this, ascending aortic banding was done in wild type mice to create pressure overload
induced heart failure and then treated with Mdivi and compared with vehicle treated controls.
Results: Expression of MMP-2, vascular endothelial growth factor, CD31, was increased, while expression of anti angiogenic
factors like endostatin and angiostatin along with MMP-9, TIMP-3 was reduced in Mdivi treated AB 8 weeks mice compared
to vehicle treated controls. Expression of mitophagy markers like LC3 and p62 was decreased in Mdivi treated mice compared
to controls. Cardiac functional status assessed by echocardiography showed improvement and there is also a decrease in the
deposition of fibrosis in Mdivi treated mice compared to controls.
Conclusion: Above results suggest that Mdivi inhibits the abnormal cardiac mitophagy response during sustained pressure
overload stress and propose the novel therapeutic role of Mdivi in ameliorating heart failure.
Suresh C Tyagi is a professor in the Department of Physiology and Biophysics in the School of Medicine at University of Louisville. His research is supported by the National Institutes of Health. He is the recipient of numerous awards and honors including a medal of merit from the International Society for Heart Research. Tyagi has published more than 156 peer-reviewed articles, invited papers, and reviews. He is currently principal investigator on four NIH grants totaling $6.2 million